The iShares Core High Dividend ETF (NYSEARCA:HDV) is BlackRock’s answer for investors who want US large-cap exposure with a bigger income stream than a plain S&P 500 fund provides. HDV tracks the Morningstar Dividend Yield Focus Index and holds roughly 81 dividend-paying companies screened for competitive moats and balance sheet strength.
The distribution profile has generated headlines in the 3.7% range on a trailing basis, though at recent prices the running yield sits closer to 3.1%. Whether HDV’s income stream is durable enough to justify holding it instead of a broad core fund depends on the quality of its underlying cash flows.
How HDV Generates Its Income
The payout comes directly from the cash dividends of its underlying companies. There are no options premiums, no bond coupons, and no return-of-capital gimmicks. The fund passes through what its holdings pay, minus a 0.08% expense ratio. Distributions arrive quarterly, and the size of each check tracks the portfolio’s underlying dividend calendar. HDV’s straightforward structure appeals to investors seeking transparent, low-cost dividend income.
The concentration is meaningful. The top 10 names account for roughly 51% of assets, and sector weights lean heavily into Health Care (23%), Energy (21%), and Consumer Staples (19%). That mix explains both the yield and the risk profile: these are mature, cash-generative industries that rarely surprise on the upside but tend to keep writing dividend checks through cycles.
The Names That Drive the Payout
Exxon Mobil (8%) and Chevron (6%) together anchor nearly 15% of the fund. Both integrated majors have covered dividends comfortably at current oil prices, and Bureau of Economic Analysis data shows durable-goods manufacturing profits climbing from $325.6 billion in Q1 2025 to $452.9 billion in Q1 2026, a backdrop that supports energy cash flows. The main vulnerability is a sustained crude downturn, which historically forces buyback cuts before dividend cuts at these two names.
AbbVie (5%) and Johnson & Johnson (6%) supply the healthcare backbone. Both carry investment-grade balance sheets and long dividend growth records. AbbVie faces the ongoing Humira biosimilar erosion, but its Skyrizi and Rinvoq franchises have absorbed the hit. J&J’s payout ratio remains well inside earnings coverage even after the consumer health spin-off.
Consumer staples exposure through Procter & Gamble (4%), Philip Morris (4%), and Coca-Cola (4%) adds the low-beta layer. Retail sector profits climbed to $422.2 billion in Q1 2026, up steadily for four quarters, which reinforces the case that staples payouts are backed by real cash generation rather than balance sheet leverage.
Total Return Versus a Core Fund
Over the past year, HDV returned 23% on price alone, ahead of the SPDR S&P 500 ETF Trust (NYSEARCA:SPY)’s 18%. Year-to-date, HDV is up 18% against SPY’s 9%. Zoom out to ten years, and the picture flips: HDV gained 141% versus SPY’s 242%. Dividend focus wins in value-friendly environments and lags during growth-led rallies.
The rate backdrop matters too, and with the Fed Funds Rate at 3.75% and the 10-year Treasury near 4.55%, HDV’s trailing yield no longer clears the risk-free rate. Investors are paying for dividend growth and equity upside rather than a pure income premium.
The Verdict on HDV’s Distribution
The dividend looks safe. Coverage is grounded in some of the strongest cash-flow generators in the US market, the 60% payout ratio at the fund level leaves cushion, and 9% dividend growth suggests income is compounding, not stagnating. The trade-off is a sector tilt that will lag when technology leads. HDV suits investors who want a quality-screened income stream and are willing to accept a value bias. Anyone expecting HDV to match a cap-weighted S&P fund across a full growth cycle will likely be disappointed.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks